Mandate

Vinge has advised Procuritas in connection with its investment in Strandberg Guitars

Vinge has advised Procuritas in connection with its investment in Strandberg Guitars, the global market leader in headless guitars under the .strandberg* brand.

Founded in 2012 by Ola Strandberg, Strandberg Guitars has established itself as the leading brand globally in headless guitars, a fast-growing niche in the electric guitar market. Headquartered in Uppsala, Sweden with local operations in California, USA the Company serves its global customer base directly online and through a wide network of renowned music retailers. Through its well-developed digital platform, Strandberg Guitars has built a large and highly engaged community of followers and musicians around the world. Since inception, the Company has had an uncompromised commitment to innovation aimed to lead the development of high-performance guitars that meet the needs of modern guitarists.

Vinge’s team consisted of, among others, Jonas Bergström, Jonas Johansson, Anna Jonsson, Carl Sander, Eléonore Friberg, Carl Trolle Olson and Alice Clarin (M&A), Lisa Hörnqvist, Karolina Fuhrman and Cecilia Cronqvist (Corporate Commercial and IT), Malin Malm Waerme and Arvid Axelryd (IP), Karin Gynnerstedt, Ebba Svenburg and Carl Östlund (Employment) and Erik Ax.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025